Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing Medical Cannabis Products. The company’s core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Kanabo is currently undertaking a pilot scheme, which will continue for a period of up to 3 months following Admission. The purpose of the Pilot is to measure a number of key performance indicators in relation to the sale of its Retail CBD Products, including consumer preferences, demands for Retail CBD Products, the effectiveness of the supply chain and compliance with quality controls.

The Company has had a 40% customer retention rate since the inception of the Pilot. The second phase will be aimed at delivering growth in sales of Kanabo’s Retail CBD Products.

Kanabo’s future strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold alongside its vaporisation device, the VapePod Medical. It is intended that Unlicensed Medical Cannabis Oils will be sold as unlicensed medicines in the UK and Germany.

General Information

Kanabo Group Plc
(Incorporated in England and Wales with Registered No. 10485105)
The Company is subject to the UK City Code on Takeovers and Mergers

Registered Office Address:
Churchill House
137-139 Brent Street

Professional Advisors

Adviser, Financial Adviser, and Broker:

Peterhouse Capital Limited
3rd Floor
80 Cheapside
London EC2V 6EE


Public & Investor Relations:

RKM Communications Ltd
Waverley House,
9 Noel Street,
London W1F 8GQ

VOX Markets
1 Poultry,
London EC2R 8EJ,
United Kingdom


Reporting Accountants and Auditors:

PKF Littlejohn LLP
15 Westferry Circus
London E14 4HD



Neville Registrars Limited
Neville House
Steelpark Road
Halesowen B62 8HD

Corporate Governance

The Directors are committed to maintaining high standards of corporate governance, and propose, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.

The Board has established Board Committees for Audit, Remuneration and Nominations and is committed to developing further policies and procedures which reflect the principles of good governance.

The Company has adopted a share dealing code for the Directors and will take steps to ensure compliance by the Directors and any relevant employees with the terms of this code.

The Directors have established financial controls and reporting procedures which are considered appropriate given the size of and structure of the Company. These controls will continue to be reviewed as the Company develops and will be revised accordingly.

Capital Structure & Shareholder Information

Total issued and outstanding 422,916,056


Directors Shareholdings percentage shareholding fully diluted
number of Options
Avihu Tamir 22.17% 0
David Tsur 2.59% 2,700,000
Daniel Poulter 0.36% 1,800,000
Andy Morrison 1.52% 900,000
Gil Efron 0.00% 0


Significant Shareholders
percentage shareholding fully diluted
David Sack 3.69%


Other Equity Instruments
Deferred Consideration based on milestones 38,461,492.00
Employees Option – exercise price 16.5p 3,150,000.00
Employees Option – exercise price 27.21p 4,000,000.00
Employees Option – exercise price 2.5p 1,348,077.00
Previous directors – exercise price 2.5p/10p 1,800,000.00
Warrants – exercise price 10p 2,928,779.00
Warrants – exercise price 6.5p 2,701,719.00
Warrants – exercise price 5p 1,150,000.00
Warrants – exercise price 16p 14,062,500 .00
Warrants – exercise price 24p 14,062,500 .00